PharmaMar receives Orphan Drug Designation for lurbinectedin from the Swiss Agency for Therapeutic Products for Malignant Mesothelioma

PharmaMar (PHM:MSE) has announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted Orphan Drug designation to lurbinectedin for the treatment of Malignant Mesothelioma. This decision is based on the orphan drug recognition granted by the European Medicines Agency in August, 2021. Malignant Mesothelioma is a tumor that arises from the mesothelial cells of the pleural, peritoneal or pericardial lining of the lung, and is often associated with exposure to asbestos, usually with a very poor prognosis at the time of diagnosis.. There is currently no cure for most malignant mesotheliomas. Therefore, the goal of current cancer treatments (surgery, radiation therapy and chemotherapy) is to reduce or eliminate symptoms, as well as to prolong Progression-Free Survival (PFS) and/or Overall Survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years, after the exposure to asbestos, as there is a long latency period after exposure before a Malignant Mesothelioma forms.

The release as fetched from its publisher. pharmamar.com ↗